Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors
Konecny, Gottfried E., Wahner Hendrickson, Andrea Elisabeth, Winterhoff, Boris, Chander, Cinthiya, Bilic, Sanela, Davenport, Simon, Chung, Adrine, Miller, Lei-Lani, Press, Michael F., Letrent, Stephen P., Slamon, Dennis J.
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer
Konecny, Gottfried, Hendrickson, Andrea Wahner, Winterhoff, Boris, Chander, Cinthiya, Bilic, Sanela, Davenport, Simon, Chung, Adrine, Miller, Lei-Lani, Press, Michael, Letrent, Stephen, Slamon, Dennis
Published in International journal of gynecological cancer (07.11.2023)
Published in International journal of gynecological cancer (07.11.2023)
Get full text
Journal Article